Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ETNB 
89bio Inc (ETNB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: ETNB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $29.3
1 Year Target Price $29.3
| 8 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.55% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.20B USD | Price to earnings Ratio - | 1Y Target Price 29.3 |
Price to earnings Ratio - | 1Y Target Price 29.3 | ||
Volume (30-day avg) 11 | Beta 1.26 | 52 Weeks Range 4.16 - 15.06 | Updated Date 10/29/2025 |
52 Weeks Range 4.16 - 15.06 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.69 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.5074 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -49.1% | Return on Equity (TTM) -86.86% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1680082631 | Price to Sales(TTM) - |
Enterprise Value 1680082631 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.75 | Shares Outstanding 148492428 | Shares Floating 97041054 |
Shares Outstanding 148492428 | Shares Floating 97041054 | ||
Percent Insiders 0.6 | Percent Institutions 105.12 |
Upturn AI SWOT
89bio Inc
Company Overview
History and Background
89bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH) and other liver-related diseases. Founded in 2018, it has advanced its lead product candidate, pegozafermin, through clinical trials.
Core Business Areas
- NASH Therapeutics: Developing and commercializing pegozafermin for the treatment of NASH.
Leadership and Structure
Dr. Rohin Shah is the CEO. The company has a typical structure for a biotech company, with departments focused on research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Pegozafermin: Pegozafermin is 89bio's lead product candidate, a glycoPEGylated FGF21 analogue being developed for the treatment of NASH and severe hypertriglyceridemia (SHTG). It is currently in Phase 3 clinical trials for NASH. Market share data is not yet available as the drug is not yet commercialized. Competitors include Madrigal Pharmaceuticals (MDGL) with resmetirom which has received accelerated FDA approval, and numerous other companies developing NASH therapies.
Market Dynamics
Industry Overview
The NASH market is a large and growing market, with significant unmet medical need. Several companies are developing therapies for NASH, but only resmetirom from Madrigal Pharmaceuticals (MDGL) has been approved to treat it.
Positioning
89bio is positioned as a company focused on developing a novel FGF21 analogue for NASH and SHTG. Pegozafermin has shown promising results in clinical trials, suggesting it could be a competitive therapy.
Total Addressable Market (TAM)
The NASH market is estimated to be worth billions of dollars. Estimates vary but range upwards to $40 billion by 2030. 89bio aims to capture a significant portion of this market with pegozafermin, assuming successful trial results and regulatory approval.
Upturn SWOT Analysis
Strengths
- Promising clinical trial results for pegozafermin
- Strong intellectual property position
- Experienced management team
- Focus on a large and growing market with unmet need
Weaknesses
- Pegozafermin is still in clinical development and not yet approved
- The company has no products generating revenue
- Reliance on a single lead product candidate
- Relatively small size compared to larger pharmaceutical companies
Opportunities
- Potential for regulatory approval of pegozafermin for NASH and SHTG
- Expansion into other liver-related diseases
- Partnerships with larger pharmaceutical companies
- Growing awareness of NASH and increased diagnosis rates
Threats
- Failure of clinical trials
- Regulatory hurdles
- Competition from other NASH therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- GILD
- ICPT
Competitive Landscape
89bio is competing in a crowded field of companies developing NASH therapies. Its FGF21 analogue approach is differentiated, but it faces competition from other mechanisms of action and established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been focused on advancing pegozafermin through clinical trials.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approval, and commercialization of pegozafermin. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 clinical trials for pegozafermin.
Summary
89bio is a clinical-stage biopharmaceutical company focused on NASH with its lead drug candidate, pegozafermin. Its success hinges on the outcome of Phase 3 clinical trials and subsequent regulatory approval. The company operates in a competitive landscape, and its financial performance is reliant on future product revenue, giving it potential but also a significant degree of risk. Pegozafermin's novel approach might offer an advantage. The company should monitor competitor developments.
Similar Stocks
Sources and Disclaimers
Data Sources:
- 89bio Inc. website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 89bio Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2019-11-11 | CEO & Director Mr. Rohan Palekar | ||
Sector Healthcare | Industry Biotechnology | Full time employees 93 | Website https://www.89bio.com |
Full time employees 93 | Website https://www.89bio.com | ||
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.